Literature DB >> 6420331

P-cell stimulating factor: characterization, action on multiple lineages of bone-marrow-derived cells and role in oncogenesis.

J W Schrader, I Clark-Lewis, R M Crapper, G W Wong.   

Abstract

T-cell hybridomas have allowed us to define unequivocally a group of 3 distinct molecules, TCGF, T-cell GM-CSF, and PSF, as the products of the activated T-cell. It is becoming increasingly evident that these T-cell-derived molecules, together with a fourth, interferon-gamma, (Wong et al. 1982, 1983), affect a wide range of cell-types. The molecule which we have studied in greatest detail, PSF, probably effects every lineage of non-lymphoid bone-marrow-derived cells. We have evidence that PSF acts in vivo as an important mediator in a pleotropic defence and repair response to antigens that involves all the non-lymphoid elements of the blood. Finally, there is evidence that PSF-dependent cells can become immortal, and that activation and functional expression of the PSF gene can occur in such cells and result in autonomy and tumorigenesis. Clonal sources of T-cell lymphokines and clonal targets for lymphokine assays, formed the basis of recent progress in defining the number and nature of non-antigen-specific T cell products; cloning of the genes coding for these lymphokines should result in a similar impetus to the investigation of the physiology and possible therapeutic role of T-cell lymphokines, and lead to new insights into the control of gene expression and the role of these factors in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6420331     DOI: 10.1111/j.1600-065x.1983.tb01098.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  10 in total

1.  Formation of functional peptide complexes of class II major histocompatibility complex proteins from subunits produced in Escherichia coli.

Authors:  J D Altman; P A Reay; M M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

2.  Nature and specificity of lymphokine independence induced by a selectable retroviral vector expressing v-src.

Authors:  R W Overell; J D Watson; B Gallis; K E Weisser; D Cosman; M B Widmer
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

3.  Effect of interleukin 3 on the differentiation and histamine content of cultured bone marrow mast cells.

Authors:  H F Chiu; B A Burrall
Journal:  Agents Actions       Date:  1990-11

4.  Rat IL-3 stimulates the growth of rat mucosal mast cells in culture.

Authors:  D M Haig; C McMenamin; J Redmond; D Brown; I G Young; S D Cohen; A J Hapel
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

5.  Growth factor gene activation and clonal heterogeneity in an autostimulatory myeloid leukemia.

Authors:  K B Leslie; J W Schrader
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

6.  Altered protein kinase C in a mast cell variant defective in exocytosis.

Authors:  N Mazurek; R Regazzi; C Borner; R Wyss; J F Conscience; P Erne; U Eppenberger; D Fabbro
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

7.  Structure of the chromosomal gene for murine interleukin 3.

Authors:  S Miyatake; T Yokota; F Lee; K Arai
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

8.  Interleukin-3-dependent expression of the c-myc and c-fos proto-oncogenes in hemopoietic cell lines.

Authors:  J F Conscience; B Verrier; G Martin
Journal:  EMBO J       Date:  1986-02       Impact factor: 11.598

9.  Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores.

Authors:  G Rodriguez-Tarduchy; M Collins; A López-Rivas
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

10.  The avidity spectrum of T cell receptor interactions accounts for T cell anergy in a double transgenic model.

Authors:  L Girgis; M M Davis; B Fazekas de St Groth
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.